The biotech rally was pure narrative vapor. $XBI ran from $70 to $170 with zero fundamental support—no breakthrough cures, no AI magic fixing drug discovery timelines. Just hype.

Now we've got a textbook head-and-shoulders top forming. The setup is clear: distribution phase complete, neckline support cracking. This is what happens when a sector pumps on dreams instead of data.

If you're still long biotech thinking AI will save it, you're holding the bag. The trade was the momentum move up. Now it's about managing the exit or positioning short. No questions needed—the chart is screaming.